VENT-01 Investigational oral systemic NLRP3 inhibitor licensed to Novo Nordisk for development across systemic inflammatory diseases.
Visit productCosigns Received
Be the first Cosign
Put your name behind VENT-01.
Add it to your Products I use list and share why you use it.